Body Mass Index (BMI) is a number calculated from a person's weight and height.BMI provides a reliable indicator of body fatness for most people and is used toscreen for weight categories that may lead to health problems.
A BMI Chart or Body Mass Index Chart can be a useful tool for visualizing the ranges for underweight, healthy weight, overweight, and obesity based on a person's height. This spreadsheet was used to create the BMI charts listed above (using quite a few special tricks which may delight the Excel enthusiast). BMI is calculated the same way for children as for adults, but the criteria for determining a "normal" weight is different. For children, the weight status category (underweight, healthy weight, overweight, and obese) is defined based on the BMI percentile (less than the 5th percentile, 5th to less than the 85th, 85th to less than the 95th, and equal to or greater than 95th, respectively). Disclaimer: This body mass index chart spreadsheet, the images, and the information on this page are for illustrative and educational purposes only.
If you want to check if your child is a healthy weight, or if you are under 18 yourself, use the BMI healthy weight calculator, which is suitable for both adults and children. Growth charts specifically for children are included in the red book (Personal Child Health Record) given to parents in most areas of England just before or after the birth of their child. If you're in any of these ranges, you're heavier than is healthy for someone of your height.
This is because having lots of muscle may put you in the overweight or obese categories, even if you have little body fat.
With an account you can keep track of pages on the site and save them to this tab, which you can access on every page when you are logged in. This height weight chart is based on body mass index and the healthy weight range shown covers both men and women. Slim women tend to be towards the lower end of the healthy weight range, whilst men could still look slim at the top end of the healthy weight range. Maintaining a healthier weight is important for protection against obesity related illness and disability. If your weight is currently over the healthy range for your height, losing some weight may be beneficial to your health, your looks, and how you feel.
To find out how many calories you need to maintain your current weight, or to reach a healthy weight, you can try out the tools in Weight Loss Resources free.
See the healthy weight range personal to you, set a Weight Loss goal, and see how many calories you need each day to get there - try the Weight Loss Resources Tools free for 24 hours. The safety and effectiveness of Qsymia in combination with other products intended for weight loss, including prescription and over-the-counter drugs and herbal preparations have not been established. Known hypersensitivity or idiosyncrasy to the sympathomimetic amines [see Adverse Reactions (6.2)]. Because of the teratogenic risk associated with Qsymia therapy, Qsymia is available through a limited program under the REMS.
A higher percentage of Qsymia-treated overweight and obese adults experienced heart rate increases from baseline of more than 5, 10, 15, and 20 beats per minute (bpm) compared to placebo-treated overweight and obese adults.
The clinical significance of a heart rate elevation with Qsymia treatment is unclear, especially for patients with cardiac and cerebrovascular disease (such as patients with a history of myocardial infarction or stroke in the previous 6 months, life-threatening arrhythmias, or congestive heart failure).
Regular measurement of resting heart rate is recommended for all patients taking Qsymia, especially patients with cardiac or cerebrovascular disease or when initiating or increasing the dose of Qsymia.
Patients should inform healthcare providers of palpitations or feelings of a racing heartbeat while at rest during Qsymia treatment. Antiepileptic drugs (AEDs), including topiramate, a component of Qsymia, increase the risk of suicidal thoughts or behavior in patients taking these drugs for any indication.
The increased risk of suicidal thoughts or behavior with AEDs was observed as early as 1 week after starting drug treatment with AEDs and persisted for the duration of treatment assessed. The risk of suicidal thoughts or behavior was generally consistent among drugs in the data analyzed. A syndrome consisting of acute myopia associated with secondary angle closure glaucoma has been reported in patients treated with topiramate, a component of Qsymia. For clinically significant or persistent symptoms consider dose reduction or withdrawal of Qsymia. Since Qsymia has the potential to impair cognitive function, patients should be cautioned about operating hazardous machinery, including automobiles, until they are reasonably certain Qsymia therapy does not affect them adversely. Hyperchloremic, non-anion gap, metabolic acidosis (decreased serum bicarbonate below the normal reference range in the absence of chronic respiratory alkalosis) has been reported in patients treated with Qsymia [see Adverse Reactions (6.1)]. Some manifestations of acute or chronic metabolic acidosis may include hyperventilation, nonspecific symptoms such as fatigue and anorexia, or more severe sequelae including cardiac arrhythmias or stupor. Measurement of electrolytes including serum bicarbonate prior to starting Qsymia and during Qsymia treatment is recommended. In hypertensive patients being treated with antihypertensive medications, weight loss may increase the risk of hypotension, and associated symptoms including dizziness, lightheadedness, and syncope. Abrupt withdrawal of topiramate, a component of Qsymia, has been associated with seizures in individuals without a history of seizures or epilepsy. In patients with mild (Child-Pugh score 5 - 6) or moderate (Child-Pugh score 7 - 9) hepatic impairment, exposure to phentermine was higher compared to healthy volunteers.
Qsymia has not been studied in patients with severe hepatic impairment (Child-Pugh score 10 - 15). Use of topiramate by patients on a ketogenic diet may also result in a physiological environment that increases the likelihood of kidney stone formation. Increase fluid intake to increase urinary output which can decrease the concentration of substances involved in kidney stone formation [see Adverse Reactions (6.1)]. Oligohidrosis (decreased sweating), infrequently resulting in hospitalization, has been reported in association with the use of topiramate, a component of Qsymia. Patients treated with Qsymia should be advised to monitor for decreased sweating and increased body temperature during physical activity, especially in hot weather.
Qsymia can increase the risk of hypokalemia through its inhibition of carbonic anhydrase activity. Qsymia was associated with changes in several clinical laboratory analytes in randomized, double-blind, placebo-controlled studies. Because clinical trials are conducted under widely varying conditions, adverse reaction rates observed in the clinical trials of a drug cannot be directly compared to rates in the clinical studies of another drug and may not reflect the rates observed in practice. Adverse reactions reported in greater than or equal to 2% of Qsymia-treated patients and more frequently than in the placebo group are shown in Table 3.
In the 1-year controlled trials of Qsymia, there was a dose-related increase from baseline, peaking between Week 4 to 8, which declined but remained elevated over baseline over 1 year of treatment.
The following adverse reactions have been reported during post approval use of phentermine and topiramate, the components of Qsymia.
Use of phentermine is contraindicated during or within 14 days following the administration of monoamine oxidase inhibitors because of the risk of hypertensive crisis. Although this study did not specifically address the impact of the interaction on contraceptive efficacy, an increased risk of pregnancy is not anticipated.
However, irregular bleeding (spotting) may occur more frequently due to both the increased exposure to the progestin and lower exposure to the estrogen, which tends to stabilize the endometrium.

Specific drug interaction studies of Qsymia and alcohol or other CNS depressant drugs have not been performed. Concurrent use of Qsymia with non-potassium sparing diuretics may potentiate the potassium-wasting action of these diuretics. Concomitant administration of phenytoin or carbamazepine with topiramate in patients with epilepsy, decreased plasma concentrations of topiramate by 48% and 40%, respectively, when compared to topiramate given alone [see Clinical Pharmacology (12.3)].
Concomitant administration of valproic acid and topiramate has been associated with hyperammonemia with and without encephalopathy. If this drug is used during pregnancy, or if a patient becomes pregnant while taking this drug, treatment should be discontinued immediately and the patient should be apprised of the potential hazard to a fetus. There is a Qsymia Pregnancy Surveillance Program to monitor maternal-fetal outcomes of pregnancies that occur during Qsymia therapy.
A minimum weight gain, and no weight loss, is currently recommended for all pregnant women, including those who are already overweight or obese, due to the obligatory weight gain that occurs in maternal tissues during pregnancy. Data evaluating the risk of major congenital malformations and oral clefts with topiramate (a component of Qsymia) exposure during pregnancy is available from the North American Anti-Epileptic Drug (NAAED) Pregnancy Registry and from several larger retrospective epidemiologic studies. Please note: If you have a promotional code you'll be prompted to enter it prior to confirming your order. If you subscribe to any of our print newsletters and have never activated your online account, please activate your account below for online access. Various herbs and other supplements have been touted for their ability to improve cholesterol levels.
As you've gotten older, have you noticed that you often find yourself marching around the house in a huff, searching for misplaced car keys or eyeglasses, or you just cannot remember the name of that new neighbor you met when walking the dog? The way you live, what you eat and drink, and how you treat your body can affect your memory just as much as your physical health and well-being. Hip and knee pain can keep you from the activities you love, as well as make routine tasks difficult. Watching the sugar in your diet can help you control your weight and potentially avoid serious chronic health problems — for example, heart disease and diabetes. The body systems responsible for balance can be affected by gradual changes due to aging or side effects of medications.
If a growth or mole looks like a melanoma, the doctor will take a biopsy to confirm the diagnosis.
Alzheimer's disease is characterized by progressive damage to nerve cells and their connections. It might seem like retirement is a time to take it easy and devote yourself to gardening, golfing, and napping. What if men approached their health at midlife the same way that financial experts advise them to plan for retirement?
Sleep shortfalls can lead to a range of health problems, from being more likely to catch a cold or gain weight to increased risk of developing heart disease or diabetes. To estimate your BMI, enter your height and weight below, then click the "Calculate" button. The Body Mass Index, or BMI, is a standard calculation based on a person's height and weight. Schedule your free consultation on-line within the next 48 hours and receive an additional $25.00 off the program of your choice. The simplicity of the BMI formula has made it extremely popular as an initial diagnosing tool for determining a person's healthy body weight. It also contains a BMI Calculator and provides tables listing the weight status categories. Instead of specific BMI thresholds, a BMI percentile is used to compare to other children of the same age and gender. However, to stay in good health, it's still important to eat a balanced diet and include physical activity in your daily life.
They can offer advice on lifestyle changes, and may refer you to a weight loss group or discuss other treatments. From how to work out your calorie needs, to how to count exercise calories, to full nutrition information for over 22,000 UK brands and basic foods .
Data from pregnancy registries and epidemiology studies indicate that a fetus exposed to topiramate, a component of Qsymia, in the first trimester of pregnancy has an increased risk of oral clefts (cleft lip with or without cleft palate).
Table 2 provides the numbers and percentages of patients with elevations in heart rate in clinical studies of up to one year. Qsymia has not been studied in patients with recent or unstable cardiac or cerebrovascular disease and therefore use is not recommended. For patients who experience a sustained increase in resting heart rate while taking Qsymia, the dose should be reduced or Qsymia discontinued. Because most trials included in the analysis did not extend beyond 24 weeks, the risk of suicidal thoughts or behavior beyond 24 weeks could not be assessed.
The finding of increased risk with AEDs of varying mechanisms of action and across a range of indications suggests that the risk applies to all AEDs used for any indication. Patients with a history of depression may be at increased risk of recurrent depression or other mood disorders while taking Qsymia. If cognitive dysfunction persists consider dose reduction or withdrawal of Qsymia for symptoms that are moderate to severe, bothersome, or those which fail to resolve with dose reduction. In Qsymia clinical trials, the peak reduction in serum bicarbonate occurred by week 4, and in most subjects there was a correction of bicarbonate by week 56, without any change to study drug.
Measurement of blood pressure prior to starting Qsymia and during Qsymia treatment is recommended in patients being treated for hypertension. In situations where immediate termination of Qsymia is medically required, appropriate monitoring is recommended.
Topiramate, a component of Qsymia, inhibits carbonic anhydrase activity and promotes kidney stone formation by reducing urinary citrate excretion and increasing urine pH. Decreased sweating and an elevation in body temperature above normal characterized these cases. Caution should be used when Qsymia is prescribed with other drugs that predispose patients to heat-related disorders; these drugs include, but are not limited to, other carbonic anhydrase inhibitors and drugs with anticholinergic activity. In addition, when Qsymia is used in conjunction with non-potassium sparing diuretics such as furosemide (loop diuretic) or hydrochlorothiazide (thiazide-like diuretic) this may further potentiate potassium-wasting. Of the subjects who experienced persistent low serum potassium, 88% were receiving treatment with a non-potassium sparing diuretic. The most common adverse reactions that led to discontinuation of treatment are shown in Table 4. Because these reactions are reported voluntarily from a population of uncertain size it is not always possible to reliably estimate their frequency or establish a causal relationship to drug exposure. The primary determinant of contraceptive efficacy is the progestin component of the combination oral contraceptive, so higher exposure to the progestin would not be expected to be deleterious. Patients should be informed not to discontinue their combination oral contraceptive if spotting occurs, but to notify their health care provider if the spotting is troubling to them.

Concomitant administration of hydrochlorothiazide alone with topiramate alone has been shown to increase the Cmax and AUC of topiramate by 27% and 29%, respectively. Concomitant administration of topiramate with valproic acid in patients has also been associated with hypothermia (with and without hyperammonemia). Avoid the use of Qsymia with other drugs that inhibit carbonic anhydrase [see Warnings and Precautions (5.7)]. The use of Qsymia can cause fetal harm and weight loss offers no potential benefit to a pregnant woman. Healthcare providers and patients are encouraged to report pregnancies by calling 1-888-998-4887.
The lip is formed between the beginning of the fifth week to the seventh week of gestation, and the palate is formed between the beginning of the sixth week through the ninth week of gestation. First, identify your weight (to the nearest 10 pounds) in one of the columns across the top, then move your finger down the column until you come to the row that represents your height. It determines the relationship between the two and generates a number which shows whether a person is underweight, optimal weight or various degrees of obesity.
The formula does have its shortcomings because it does not take into account age, frame size, gender, or muscularity. Just as there are Weight-for-Age, Height-for-Age, and Head Circumference-for-Age growth charts, there are also BMI-for-Age charts. A BMI conversion chart (Table 1) based on height [inches (in) or centimeters (cm)] and weight [pounds (lb) or kilograms (kg)] is provided below. If Qsymia is used during pregnancy or if a patient becomes pregnant while taking Qsymia, treatment should be discontinued immediately, and the patient should be apprised of the potential hazard to a fetus.
There were four suicides in AED-treated patients in the trials and none in placebo treated patients, but the number is too small to allow any conclusion about AED effect on suicide. The risk did not vary substantially by age (5 to 100 years) in the clinical trials analyzed. Ophthalmologic findings can include myopia, anterior chamber shallowing, ocular hyperemia (redness), and increased intraocular pressure. The majority of these mood and sleep disorders resolved spontaneously, or resolved upon discontinuation of dosing [see Adverse Reactions (6.1)].
Therefore, if Qsymia is given concomitantly with another carbonic anhydrase inhibitor to a patient with a predisposing condition for metabolic acidosis the patient should be monitored for the appearance or worsening of metabolic acidosis. The effect of Qsymia on growth and bone-related sequelae has not been systematically investigated in long-term, placebo-controlled trials.
However, if persistent metabolic acidosis develops while taking Qsymia, reduce the dose or discontinue Qsymia. On average, serum creatinine gradually declined but remained elevated over baseline creatinine values. Measurement of blood glucose levels prior to starting Qsymia and during Qsymia treatment is recommended in patients with type 2 diabetes. If a patient develops symptoms associated with low blood pressure after starting Qsymia, appropriate changes should be made to the antihypertensive drug regimen.
Some of the cases have been reported with topiramate after exposure to elevated environmental temperatures. The majority of these events first occurred within the initial 12 weeks of drug therapy; however, in some patients, events were reported later in the course of treatment. These events typically began within the first 4 weeks of treatment, had a median duration of approximately 28 days or less, and were reversible upon discontinuation of treatment; however, individual patients did experience events later in treatment, and events of longer duration. Therefore, if Qsymia is used with alcohol or other CNS depressants, the patient should be counseled regarding possible increased risk of CNS depression or side effects.
It may be prudent to examine blood ammonia in patients in whom the onset of hypothermia or encephalopathy has been reported [see Clinical Pharmacology (12.3)]. Available epidemiologic data indicate an increased risk in oral clefts (cleft lip with or without cleft palate) with first trimester exposure to topiramate, a component of Qsymia. Larger retrospective epidemiology studies showed that topiramate monotherapy exposure in pregnancy is associated with an approximately two to five-fold increased risk of oral clefts (Table 5). Inside the square where your weight and height meet is a number that is an estimate of your BMI. It is important to note that this is simply an indicator of a person's health, and does not take into account different degrees of muscularity or body type. Females of reproductive potential should have a negative pregnancy test before starting Qsymia and monthly thereafter during Qsymia therapy.
Elevations in serum creatinine often signify a decrease in renal function, but the cause for Qsymia-associated changes in serum creatinine has not been definitively established. Decreases in medication doses for antidiabetic medications which are non-glucose-dependent should be considered to mitigate the risk of hypoglycemia. Only Qsymia-treated patients discontinued treatment due to these events (1% for paraesthesia and 0.6% for dysgeusia).
When multiple species of pregnant animals received topiramate at clinically relevant doses, structural malformations, including craniofacial defects, and reduced fetal weights occurred in offspring.
Use the BMI in conjunction with other measures like percentage of body fat to accurately judge your weight. This syndrome may be associated with supraciliary effusion resulting in anterior displacement of the lens and iris, with secondary angle closure glaucoma. Therefore, measurement of serum creatinine prior to starting Qsymia and during Qsymia treatment is recommended. If a patient develops hypoglycemia after starting Qsymia, appropriate changes should be made to the antidiabetic drug regimen.
Symptoms typically occur within 1 month of initiating treatment with topiramate but may occur at any time during therapy.
If persistent elevations in creatinine occur while taking Qsymia, reduce the dose or discontinue Qsymia [see Adverse Reactions (6.1)].
The majority of these events first occurred within the initial 12 weeks of drug therapy; however, in some patients, events were reported later in the course of treatments.
In the Qsymia clinical trials, the overall prevalence of mood and sleep adverse reactions was approximately twice as great in patients with a history of depression compared to patients without a history of depression; however, the proportion of patients on active treatment versus placebo who reported mood and sleep adverse reactions was similar in these two subgroups. Elevated intraocular pressure of any etiology, if left untreated, can lead to serious adverse events including permanent loss of vision.
Occurrence of depression-related events was more frequent in patients with a past history of depression across all treatment groups.
However, the placebo-adjusted difference in incidence of these events remained constant between groups regardless of previous depression history.

Diet pills to make you lose weight xenical
Best way to lose weight riding a bike
Healthy ways to lose weight without dieting


  1. iko_Silent_Life

    Cut from your every day with the.


  2. mafia4ever

    Activity is also a large cholesterol sufferers in thoughts and include components think you must weigh, it really.


  3. 123321

    So as you can get regime (much more protein & fiber and.